Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TBPH message board posts where the ticker symbol TBPH has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TBPH SEC Filings

Filings Format Description Filing Date File/Film Number
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010406 (34 Act)  Size: 11 KB
2017-12-07 001-36033
171243672
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014567 Size: 4 KB
2017-11-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014566 Size: 4 KB
2017-11-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014565 Size: 4 KB
2017-11-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014564 Size: 4 KB
2017-11-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014563 Size: 4 KB
2017-11-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014562 Size: 4 KB
2017-11-22
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014561 Size: 4 KB
2017-11-22
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001104659-17-066731 (34 Act)  Size: 3 MB
2017-11-08 001-36033
171184764
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-17-066630 (34 Act)  Size: 2 MB
2017-11-07 001-36033
171183399
More TBPH SEC Filings


Related news from
Fri, 08 Dec 2017
13:03:45 +0000
See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
Theravance Biopharma Inc NASDAQ NMS:TBPH
Tue, 28 Nov 2017
12:00:00 +0000
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
DUBLIN, Nov. 28, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted the filing of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for the use of Trelegy Ellipta, the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in a single ELLIPTA® inhaler, for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). If this sNDA is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy. Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva (formerly Theravance, Inc.).
Tue, 21 Nov 2017
13:30:00 +0000
Theravance Biopharma to Present at Two Upcoming Investor Conferences
The conference will be held November 28 - 29 at the Lotte New York Palace Hotel. Evercore ISI Biopharma Catalyst/Deep Dive Conference on Wednesday, November 29, 2017 at 8:45 am ET. The conference will be held November 29 - 30 at the Boston Harbor Hotel.
Fri, 17 Nov 2017
21:41:09 +0000
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Thu, 16 Nov 2017
21:12:00 +0000
Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD
DUBLIN, Nov. 16, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today highlighted that the European Commission has granted marketing authorization for Trelegy Ellipta, the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA® inhaler, as a maintenance treatment for appropriate patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by GlaxoSmithKline (GSK) or one of its affiliates pursuant to its agreements with Innoviva (formerly Theravance, Inc.).
Tue, 14 Nov 2017
21:53:09 +0000
Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin
Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.
Mon, 13 Nov 2017
14:28:00 +0000
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Nov. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) as a once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease (COPD). The NDA is supported by the companies' Phase 3 program for revefenacin, which consisted of two replicate pivotal Phase 3 efficacy studies and a 12-month, open-label, active comparator safety study.
Fri, 10 Nov 2017
23:40:46 +0000
Edited Transcript of TBPH earnings conference call or presentation 7-Nov-17 10:00pm GMT
Q3 2017 Theravance Biopharma Inc Earnings Call
Tue, 07 Nov 2017
21:02:00 +0000
Theravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update
Inflection Points for Key Development Programs Anticipated Throughout 2018 Trelegy Ellipta Launch Expected by Year-End 2017 DUBLIN , Nov. 7, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ...
Wed, 01 Nov 2017
12:30:00 +0000
Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional positive efficacy data from the three-month, pivotal Phase 3 studies of revefenacin (TD-4208) at the 2017 CHEST annual meeting in Toronto, Ontario. Revefenacin is an investigational long-acting muscarinic antagonist (LAMA) and a proposed once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease (COPD). James F. Donohue, MD, Professor of Medicine, Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill, presented new data from the completed three-month Phase 3 studies, which included more than 1,250 patients with moderate to very severe COPD, in two separate presentations.
Wed, 01 Nov 2017
10:00:00 +0000
Theravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland
DUBLIN, Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") today announced the opening of a new corporate office in Dublin, further establishing the Company's presence in Ireland. The Company plans to expand its Dublin employee base by hiring 30 highly-skilled professionals over the next two years in areas such as clinical development, finance, and technical operations.
Tue, 31 Oct 2017
12:30:00 +0000
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR™ Observational Patient Registry at 2017 CHEST Annual Meeting
DUBLIN, Oct. 31, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that positive preliminary new data from the Telavancin Observational Use Registry (TOUR™) study were presented at the 2017 CHEST annual meeting, being held in Toronto, Ontario on October 28 – November 1, 2017. TOUR is designed to report how VIBATIV® (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings. The presented findings, which focus on a preliminary review of data from registry patients with diagnoses of lower respiratory tract infections (LRTIs), report positive clinical responses for VIBATIV treatment of 67.1% in this infection type.
Mon, 30 Oct 2017
12:30:00 +0000
Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017
DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2017 after market close on Tuesday, November 7, 2017. An accompanying conference call will be held at 5:00 pm ET on November 7, 2017.  To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 96855845. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through December 5, 2017.
Wed, 25 Oct 2017
12:15:46 +0000
Theravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : October 25, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Theravance Biopharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more <b>(Read more...)</b>



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is the most knowledgable group I've ever been associated with (23 years). It is also the most unselfish and there is never any name calling or putting members down. ValueForum has helped me be very successful." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards